Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) including post-chimeric antigen receptor T-cell therapy (CAR T) patients: Insights from the real-world epcoritamab patient characteristics and outcomes research (Real-EPCOR) study

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYucai WangMJMonika JunAMAlex Mutebi

Discussion

Loading...

Member takes

Overview

Observational study reveals 50% ORR and 29% CR in R/R DLBCL, indicating potential benefits for post-CAR T patients.

Key Points

  • To evaluate the effectiveness of epcoritamab in a heterogeneous population with relapsed/refractory diffuse large B-cell lymphoma.
  • Multicenter US retrospective chart review study
  • Patients with R/R DLBCL who initiated epcoritamab after 5/19/23
  • Collected data on ECOG performance status, refractory status, prior CAR T, and CD20+ status
  • 50% overall response rate and 29% complete response in the overall evaluable population
  • Among patients receiving ≥2 cycles of epcor, ORR was 85%, CR rate was 54%
  • Among post-CAR T patients, ORR was 53%, CR rate was 33%

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5e2https://doi.org/10.1182/blood-2025-8075
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-32025 · 2 citations
  2. 2Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6.2024 · 1 citations
  3. 3Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab2025
  4. 4Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  5. 5Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).2024 · 9 citations